News

Patients will be at least 18 years of age with a maximum of 10% treatable body surface area (BSA) involvement of plaque psoriasis. Up to 15 patients will

Anavex Life Sciences president and CEO Christopher U. Missling said: "The Orphan Drug Designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease

PDI Therapeutics will focus on the development of novel stand-alone or combination immunotherapies to enlist the body’s immune system for fighting cancer. The company is named for protein

Plumiaz failed to demonstrate its bioequivalence to Diastat rectal gel, which was required to support a refiling of the nasal spray’s new drug application earlier planned for the

Pfizer’s application was based a clinical trial dataset of about 20,800 adolescents, as well as adults aged 10 years and older, studied across the globe. The company noted

The studies have been designed to give an array of additional data on reduction in symptoms, efficacy, quality of life benefits, to improve understanding about heart failure and

The engagement will leverage the capabilities of Inovalon’s data platforms and Avalere’s extensive industry experience, to support Bristol-Myers Squibb’s real-world outcomes and value-based contracting initiatives. The application of

EVK-001 is the Company’s novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women. Pursuant to the agreement, COSMA

VYXEOS is an investigational product in development as a treatment for AML and other blood cancers.’ The Breakthrough Therapy designation is primarily based upon the positive results from